Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).

Elizabeth R. Kessler,Junxiao Hu,Geetika Srivastava,Douglas Jerome Kemme,Praveena Iruku,Vishal Rana,Steven R. Schuster,Mali Amirault,Eryn Callihan,Thomas W. Flaig,Elaine Tat Lam

Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).

2021

Elizabeth R. Kessler
Junxiao Hu
Geetika Srivastava
Douglas Jerome Kemme
Praveena Iruku
Vishal Rana
Steven R. Schuster
Mali Amirault
Eryn Callihan
Thomas W. Flaig
Elaine Tat Lam

4544Background: Checkpoint inhibitors (CPI) and vascular endothelial growth factor receptor inhibitors (VEGFi) are standard treatments for patients (pts) with mRCC. This phase I/II study evaluated ...

Keywords:

Cancer research
Renal cell carcinoma
Medicine
Pembrolizumab
Cabozantinib
Vascular Endothelial Growth Factor Receptor
phase i ii
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations